GlassScriptPhysician profile
George Y Kunze
NPI 1659356541
$9,620.50
in general payments reported to CMS, 2019-2025
36 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $433 · 2021: $1,192 · 2022: $1,673 · 2023: $1,912 · 2024: $1,602 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,056 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,056.36 |
| Education | $126.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,186.88 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,746.17 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $863.75 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $801.49 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $461.01 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $329.17 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $292.17 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $282.72 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $258.94 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $250.74 | 2019-2025 | Sutab, Suflave |
| Celgene Corporation | $193.59 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $187.00 | 2022-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $186.72 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $164.47 | 2025 | Iqirvo |
| Lilly USA, LLC | $158.19 | 2024-2025 | Omvoh |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $156.42 | 2019-2025 | |
| Exact Sciences Corporation | $125.40 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cook Medical LLC | $107.81 | 2019-2023 | Caesar |
| Nestle Healthcare Nutrition INC. | $94.83 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $93.95 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $79.86 | 2019-2024 | Dificid |
| Genzyme Corporation | $79.36 | 2023-2025 | |
| Ucb, INC. | $78.48 | 2019-2020 | |
| Organon LLC | $62.29 | 2023-2025 | Hadlima, Renflexis |
| Ambu INC. | $56.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.50 | 2023-2024 | Cyltezo |
| Celltrion USA INC. | $44.42 | 2024-2025 | Zymfentra, Vegzelma |
| Redhill Biopharma INC. | $39.27 | 2021 | |
| Qol Medical, LLC | $38.43 | 2019-2021 | |
| Daiichi Sankyo INC. | $31.30 | 2022 | |
| Amgen INC. | $27.18 | 2023 | Amjevita, Avsola |
| Astrazeneca Pharmaceuticals LP | $24.53 | 2019-2020 | |
| Echosens North America, INC. | $21.35 | 2023 | Fibroscan |
| Novo Nordisk INC | $19.88 | 2023 | Wegovy |
| Endo Pharmaceuticals INC. | $13.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kunze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.